super responders to tirzepatide Decoding the hallmarks of GLP-1RA weight-loss What does “super responder” actually
Description
Yang Y, Lv J, Jiang S, Ma Z, Wang D, Hu W, Deng C, Fan C, Di S, Sun Y, et al
Zepbound was approved a year and a half later, in November 2023, for chronic weight management in adults with obesity as well as those who are overweight and have at least one weight-related condition (like high blood pressure or high cholesterol)
In the SURPASS-2 study, the three doses of tirzepatide (5, 10, and 15 mg once weekly) were tested with the GLP-1RA semaglutide (1 mg once weekly) as a comparator in patients not optimally controlled on monotherapy with metformin (71)
The SURPASS and SURMOUNT trials have led the ADA to consider tirzepatide, along with semaglutide, to be very highly efficacious for weight loss [38]
Want to know what the research says about which medication is more effective
At the 2.5 mg starting dose, that concentration works perfectly because you only need 25 units
